Reported positive (2)
- Primary ovarian rhabdomyosarcoma in children
Case report · Limited evidence · May 2008 - Pleuropulmonary blastoma
Case report · Limited evidence · Aug 2001
Vincristine
Evidence at a glanceHuman · observationalMixed results⚠ Studies disagree
4 published studies tagged to this agent1 human studies approved & graded (trial, observational, or meta-analysis)
Why this grade?
Human · observational — Human observational evidence only — no trials.
- 1 human · 0 animal · 0 lab · 3 review/other
- Most authoritative study: Mixed mesodermal sarcoma of the ovary. Treatment with combination radiation therapy and chemotherapy
- Studies disagree on the reported direction (conflict flagged).
- Findings conflict across studies
- Effect sizes reported in only 2 of 4 studies
- All studies are small (n < 30)
Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.
Auto-discovered · not yet curatedvincristine
Educational only, not medical advice. OncoForge makes no claim that Vincristine treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.
Simple Summary
Auto-discovered from 2 recent studies; not yet curated.
Research
Where the evidence is
What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.
CancerHuman evidenceMechanismSafetyTrial
Mixed Mesodermal Sarcoma Of The Ovary1———
- Mixed mesodermal sarcoma of the ovary. Treatment with combination radiation therapy and chemotherapy Human · observationalMixed results
Ovarian Rhabdomyosarcoma—1—1
- Primary ovarian rhabdomyosarcoma: A diagnostic dilemma in an uncommon tumor Case reportInconclusive
- Primary ovarian rhabdomyosarcoma in children Case reportReported positive
Alveolar Rhabdomyosarcoma———1
- Primary ovarian rhabdomyosarcoma in children Case reportReported positive
Embryonal Rhabdomyosarcoma———1
- Primary ovarian rhabdomyosarcoma in children Case reportReported positive
Lung Neoplasm————
- Pleuropulmonary blastoma Case reportReported positive
Pleural Neoplasm————
- Pleuropulmonary blastoma Case reportReported positive
Pleuropulmonary Blastoma————
- Pleuropulmonary blastoma Case reportReported positive
Pulmonary Blastoma————
- Pleuropulmonary blastoma Case reportReported positive
Reported figures
Study mix
4 published studies by what they were done in. Lab and animal findings often do not carry over to people.
1 Human3 Review/other
Reported directionReported positive2Mixed results1Inconclusive1
What supports this page
The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.
Guideline0
Meta-analysis0
Systematic review0
Randomized trial0
Clinical trial0
Observational1
Case report3
Review0
Preclinical0
Other0
4 studies1 human3 review/other
Tracking 4 published studies of Vincristine: 1 in humans, 3 reviews/other.
Reported direction across studies: 2 positive, 1 mixed, 1 inconclusive.
Findings conflict — both supportive and negative/mixed results exist (see below). Human evidence is limited.
These counts summarize what the studies reported; they are not a measure of whether Vincristine works.
Cancers named in these studies
Conflicting evidence
Negative or mixed (1)
- Mixed mesodermal sarcoma of the ovary. Treatment with combination radiation therapy and chemotherapy
Human · observational · Limited evidence · Oct 1983
All studies
Case reportInconclusiveLimited evidenceTier 3 · early humann = 1
Primary ovarian rhabdomyosarcoma: A diagnostic dilemma in an uncommon tumor
Journal of cancer research and therapeutics · Oct 2025 · case report
This case report describes a 17-year-old girl with a very rare ovarian rhabdomyosarcoma. The tumor was diagnosed by imaging, pathology, and immunohistochemistry, and it came back within 3 months after surgery. The authors report that she then received VAC chemotherapy (vincristine, actinomycin D, and cyclophosphamide), and they emphasize the need for earlier diagnosis and more standardized treatment approaches.
Studied with: vincristine, actinomycin D, cyclophosphamide.
Key findings
- Imaging showed a large solid-cystic pelvic mass.
- Histopathology and immunohistochemical markers (desmin, myogenin, WT1) confirmed ovarian rhabdomyosarcoma.
- Recurrence occurred within 3 months after surgical resection.
- VAC chemotherapy was given after early relapse.
Limitations: Single-patient case report.; No control group.; No quantitative treatment outcome data reported.; Cannot determine effectiveness of VAC from this report alone.; Focus is diagnostic and descriptive rather than evaluative..
Describes a rare ovarian cancer case and subsequent chemotherapy, but does not evaluate a compound's anticancer effect in a comparative way.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
Case reportTrialReported positiveLimited evidenceTier 3 · early humann = 2
Primary ovarian rhabdomyosarcoma in children
Pediatric surgery international · May 2008 · case reports
CyclophosphamideVincristineDoxorubicinovarian rhabdomyosarcomaalveolar rhabdomyosarcomaembryonal rhabdomyosarcoma
This report describes two children with very rare primary ovarian rhabdomyosarcoma. After complete surgical removal, both received chemotherapy with vincristine, doxorubicin, and cyclophosphamide and had a good response. Both patients were alive 8 and 9 months after surgery.
Key findings
- Two pediatric cases of primary ovarian rhabdomyosarcoma were described.
- Both patients underwent complete resection of the primary tumor.
- Both received vincristine, doxorubicin, and cyclophosphamide chemotherapy.
- The abstract reports a good response to therapy and survival at 8 and 9 months post-operatively.
Limitations: Case report with only 2 patients.; No control group.; Short follow-up.; Cannot separate the effect of surgery from chemotherapy.; No dosing details reported..
Describes management of a rare ovarian cancer in children, including chemotherapy, but does not isolate the effect of any single compound.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
Case reportReported positiveLimited evidenceTier 3 · early humann = 1
Pleuropulmonary blastoma
European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie · Aug 2001 · Case report
IfosfamideVincristineActinomycin-dpleuropulmonary blastomapulmonary blastomalung neoplasmpleural neoplasm
This is a single-case report of a 3-year-old boy with pleuropulmonary blastoma who underwent radical resection (bilobectomy) followed by monthly cycles of ifosfamide, vincristine and actinomycin D for 10 months. Histology showed blastemal and mesenchymal areas with rhabdomyoblastic and liposarcomatous differentiation. The patient was alive and disease-free two years after diagnosis; the authors state the favorable outcome is probably due to the radical resection.
Reported effects: chemotherapy duration 10 months 10 mo, n=1 · disease-free follow-up 2 years 2, n=1
Studied with: ifosfamide + vincristine + actinomycin D, surgical resection (bilobectomy).
Key findings
- Radical resection of the mass was achieved by bilobectomy.
- Histology showed blastemal and mesenchymal areas with focal rhabdomyoblastic and liposarcomatous differentiation.
- Monthly cycles of chemotherapy with ifosfamide, vincristine and actinomycin D were given for 10 months after surgery.
- The patient was alive and disease-free two years after diagnosis.
- Authors suggest complete tumour ablation is essential to prevent local recurrence and that the favourable outcome is probably due to radical resection.
Limitations: Single-patient case report (n=1) limits generalizability.; No control or comparison group, so causality between interventions and outcome cannot be established.; No specific chemotherapy dose amounts provided in the abstract.; Short-to-moderate follow-up (two years) for long-term outcomes is limited..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed
Human · observationalMixed resultsLimited evidenceTier 3 · early humann = 12
Mixed mesodermal sarcoma of the ovary. Treatment with combination radiation therapy and chemotherapy
Cancer · Oct 1983 · retrospective case series
This retrospective report reviews 20 patients with ovarian mixed mesodermal sarcoma and focuses on 12 patients treated after surgery with combined radiation and VAC chemotherapy (vincristine, dactinomycin, cyclophosphamide). Four of the 12 had complete tumor control (one alive without disease beyond 5 years, three died of unrelated causes without disease at autopsy) and one other had an 18-month disease-free interval. The authors state that combination radiation plus VAC appears effective compared to prior reports but note myelosuppression and gastrointestinal and neurologic toxicities, and they recommend treatment modifications.
Reported effects: total patients reviewed - count 20 · patients treated post-operatively with combination therapy - count 12 · +4 more
Studied with: radiation therapy.
Key findings
- Twenty patients with mixed mesodermal sarcoma of the ovary were reviewed.
- This report focuses on 12 patients treated post-operatively with combination radiation therapy and chemotherapy with vincristine, dactinomycin, and cyclophosphamide (VAC).
- There were 4 patients achieving complete tumor control, including one who is alive without disease beyond 5 years and 3 who died of unrelated causes without disease at autopsy.
- One other patient had a significant disease-free interval of 18 months.
- Compared to previous reports, combination radiation and VAC chemotherapy appears effective in this disease.
- Myelosuppression and gastrointestinal and neurologic toxicities were observed and treatment modifications have been recommended.
Limitations: Small sample size (focused on 12 treated patients).; Retrospective case series without a control group.; Single-center experience.; Limited detail on dosing, toxicity grading, and follow-up duration for all patients..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
What changed recently
The latest additions to Vincristine's evidence base, and anything that's been retracted.
Recently added- Pleuropulmonary blastoma Case report · added Jul 2026
- Mixed mesodermal sarcoma of the ovary. Treatment with combination radiation therapy and chemotherapy Human · observational · added Jun 2026
- Primary ovarian rhabdomyosarcoma: A diagnostic dilemma in an uncommon tumor Case report · added Jun 2026
- Primary ovarian rhabdomyosarcoma in children Case report · added Jun 2026
Cancers where Vincristine reported positive results
Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.
Preclinical only: lab / animal (7)
Ovarian rhabdomyosarcoma1 positive
Limitations: Case report with only 2 patients.; No control group.; Short follow-up.; Cannot separate the effect of surgery from chemotherapy.; No dosing details reported..
Cited positive studies (1)
- Primary ovarian rhabdomyosarcoma in children Case report · May 2008
Alveolar rhabdomyosarcoma1 positive
Limitations: Case report with only 2 patients.; No control group.; Short follow-up.; Cannot separate the effect of surgery from chemotherapy.; No dosing details reported..
Cited positive studies (1)
- Primary ovarian rhabdomyosarcoma in children Case report · May 2008
Embryonal rhabdomyosarcoma1 positive
Limitations: Case report with only 2 patients.; No control group.; Short follow-up.; Cannot separate the effect of surgery from chemotherapy.; No dosing details reported..
Cited positive studies (1)
- Primary ovarian rhabdomyosarcoma in children Case report · May 2008
Pleuropulmonary blastoma1 positive
Limitations: Single-patient case report (n=1) limits generalizability.; No control or comparison group, so causality between interventions and outcome cannot be established.; No specific chemotherapy dose amounts provided in the abstract.; Short-to-moderate follow-up (two years) for long-term outcomes is limited..
Cited positive studies (1)
- Pleuropulmonary blastoma Case report · Aug 2001
Pulmonary blastoma1 positive
Limitations: Single-patient case report (n=1) limits generalizability.; No control or comparison group, so causality between interventions and outcome cannot be established.; No specific chemotherapy dose amounts provided in the abstract.; Short-to-moderate follow-up (two years) for long-term outcomes is limited..
Cited positive studies (1)
- Pleuropulmonary blastoma Case report · Aug 2001
Lung neoplasm1 positive
Limitations: Single-patient case report (n=1) limits generalizability.; No control or comparison group, so causality between interventions and outcome cannot be established.; No specific chemotherapy dose amounts provided in the abstract.; Short-to-moderate follow-up (two years) for long-term outcomes is limited..
Cited positive studies (1)
- Pleuropulmonary blastoma Case report · Aug 2001
Pleural neoplasm1 positive
Limitations: Single-patient case report (n=1) limits generalizability.; No control or comparison group, so causality between interventions and outcome cannot be established.; No specific chemotherapy dose amounts provided in the abstract.; Short-to-moderate follow-up (two years) for long-term outcomes is limited..
Cited positive studies (1)
- Pleuropulmonary blastoma Case report · Aug 2001
Evidence at a glance: Vincristine by cancer
A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.
Human observational evidence only — no trials.
Largest credible effect: complete tumor control - count 4, n=12 PMID 6616409 · effect sizes 1–20 across 6 studies
Most authoritative study: Mixed mesodermal sarcoma of the ovary. Treatment with combination radiation therapy and chemotherapy
Based on a single study.
No primary experimental studies yet.
Most authoritative study: Primary ovarian rhabdomyosarcoma: A diagnostic dilemma in an uncommon tumor
No human studies yet · No numeric effect sizes reported · All studies are small (n < 30).
No primary experimental studies yet.
Most authoritative study: Primary ovarian rhabdomyosarcoma in children
No human studies yet · No numeric effect sizes reported · Based on a single study.
No primary experimental studies yet.
Most authoritative study: Primary ovarian rhabdomyosarcoma in children
No human studies yet · No numeric effect sizes reported · Based on a single study.
No primary experimental studies yet.
Largest credible effect: chemotherapy duration 10 months 10 mo, n=1 PMID 11558020 · effect sizes 2–10 across 2 studies
Most authoritative study: Pleuropulmonary blastoma
No human studies yet · Based on a single study.
Pleural neoplasmInsufficient evidenceReported positive
No primary experimental studies yet.
Largest credible effect: chemotherapy duration 10 months 10 mo, n=1 PMID 11558020 · effect sizes 2–10 across 2 studies
Most authoritative study: Pleuropulmonary blastoma
No human studies yet · Based on a single study.
No primary experimental studies yet.
Largest credible effect: chemotherapy duration 10 months 10 mo, n=1 PMID 11558020 · effect sizes 2–10 across 2 studies
Most authoritative study: Pleuropulmonary blastoma
No human studies yet · Based on a single study.
Pulmonary blastomaInsufficient evidenceReported positive
No primary experimental studies yet.
Largest credible effect: chemotherapy duration 10 months 10 mo, n=1 PMID 11558020 · effect sizes 2–10 across 2 studies
Most authoritative study: Pleuropulmonary blastoma
No human studies yet · Based on a single study.
Dose: as studied, not a recommendation
These are doses as studied or reported, never a recommendation. The right amount of Vincristine depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.
Doses reported in studies- Pleuropulmonary blastoma monthly cycles for 10 months; specific dose amounts not specified · Case report · Aug 2001
Clinical trials studying Vincristine
6 ongoing · 23 completed · tracked from ClinicalTrials.gov. Recruiting is not the same as proven, and completed is not the same as positive — read the results. Not a recommendation.
Completed
- Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With NeuroblastomaNCT00002634Phase 2Completed Wed Sep 01tests Etoposidetests Cyclophosphamidetests Cisplatintests Vincristinetests Doxorubicin
- A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
- Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic RhabdomyosarcomaNCT01055314Phase 2Completed Wed Jun 01tests Etoposidetests Cyclophosphamidetests Temozolomidetests Vincristinetests Ifosfamidetests DoxorubicinPrimary outcome measured: Feasibility of the Addition of Cixutumumab to Chemotherapy Determined by Patient Enrollment
- Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney TumorsNCT00002610Phase 3Completed Wed Feb 01tests Etoposidetests Cyclophosphamidetests Carboplatintests Vincristinetests Doxorubicin
- Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous SystemNCT00867178Phase 1Completed Wed Dec 22tests Carboplatintests Cyclophosphamidetests Etoposidetests Cisplatintests Vincristine
- Combination Chemotherapy in Treating Male Patients With Germ Cell TumorsNCT00301782Phase 2Completed Tue Jun 01tests Etoposidetests Carboplatintests Cisplatintests Vincristine
- Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney TumorsNCT00335556Phase 2Completed Tue Dec 01tests Carboplatintests Etoposidetests Cyclophosphamidetests Vincristinetests DoxorubicinPrimary outcome measured: Event-Free Survival of Patients With Diffuse Anaplastic Wilms' Tumor (DAWT)
- Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue SarcomaNCT00002898Phase 3Completed Tue Dec 01tests Etoposidetests Cyclophosphamidetests Carboplatintests Vincristinetests Ifosfamide
- Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone CancerNCT00002466Phase 2Completed Sun May 01tests Cyclophosphamidetests Etoposidetests Ifosfamidetests Vincristinetests Doxorubicin
- Combination Chemotherapy in Treating Infants With Newly Diagnosed NeuroblastomaNCT00025610Phase 2Completed Sun Mar 01tests Carboplatintests Cyclophosphamidetests Etoposidetests Vincristinetests Doxorubicin
- Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk NeuroblastomaNCT01798004Phase 1Completed Sun Jun 30tests Cisplatintests Vincristinetests Doxorubicintests Topotecantests Cyclophosphamidetests EtoposidePrimary outcome measured: The Tolerability of BuMel Regimen
- High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or EctomesenchymomaNCT00354744Phase 3Completed Sun Jun 30tests Cyclophosphamidetests Etoposidetests Ifosfamidetests Vincristinetests DoxorubicinPrimary outcome measured: Number of Patients With Complete or Partial Response Assessed by RECIST Criteria
- Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid TumorPrimary outcome measured: Progression-Free Survival (PFS) in ERBB2-Negative Tumors Compared to ERBB2-Positive Tumors
- Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord TumorsNCT00003141Phase 1Completed Sat Oct 01tests Carboplatintests Cyclophosphamidetests Etoposidetests Cisplatintests Vincristine
- Combination Chemotherapy in Treating Young Patients Who Are Undergoing Surgery and an Autologous Bone Marrow Transplant for Disseminated NeuroblastomaNCT00365755Phase 3Completed Sat Mar 01tests Carboplatintests Cyclophosphamidetests Etoposidetests Cisplatintests Vincristine
- Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma
- Combination Chemotherapy in Treating Patients With SarcomaNCT00662233Early Phase 1Completed Mon Oct 21tests Cyclophosphamidetests Etoposidetests Ifosfamidetests Vincristinetests Doxorubicin
- Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive RhabdomyosarcomaNCT00025363Phase 2Completed Mon Oct 01tests Cyclophosphamidetests Etoposidetests Vincristinetests Ifosfamidetests Doxorubicin
- Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal TumorsNCT00025441Phase 2Completed Mon Mar 01tests Etoposidetests Cyclophosphamidetests Carboplatintests Vincristinetests Ifosfamidetests Doxorubicin
- Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell LymphomaNCT01606878Phase 1Completed Mon Dec 31tests Vincristinetests Doxorubicintests Topotecantests Cyclophosphamidetests CrizotinibPrimary outcome measured: Maximum Tolerated Dose (MTD) of Crizotinib
- Combination Chemotherapy Before Surgery in Treating Children With Localized NeuroblastomaNCT00025428Phase 3Completed Fri Nov 01tests Carboplatintests Cyclophosphamidetests Etoposidetests Vincristinetests Doxorubicin
- Combination Chemotherapy or Observation Following Surgery in Treating Infants With Neuroblastoma
- Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney CancerNCT00002611Phase 3Completed Fri Aug 01tests Etoposidetests Cyclophosphamidetests Vincristinetests DoxorubicinResults paper (PMID 22952427) →Results paper (PMID 21189373) →Results paper (PMID 18989885) →Results paper (PMID 19208794) →Results paper (PMID 17539021) →Results paper (PMID 16710034) →Results paper (PMID 16410127) →Results paper (PMID 16172460) →Results paper (PMID 15868587) →Results paper (PMID 16129848) →Results paper (PMID 15654272) →Results paper (PMID 37933882) →
Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.